Evaluation of Factors Influencing Specialist Referral Among Individuals Tested Positive for HBsAg in Health Check Programs in Hong Kong
- PMID: 41338667
- DOI: 10.1111/jgh.70151
Evaluation of Factors Influencing Specialist Referral Among Individuals Tested Positive for HBsAg in Health Check Programs in Hong Kong
Abstract
Background and aims: Linkage of hepatitis B virus (HBV)-infected individuals to medical care is a major hurdle in the HBV elimination care cascade. This study aimed to investigate the rate and factors influencing specialist referral of HBV cases identified in health check programs.
Methods: This was a retrospective study among consecutive individuals undergoing health check programs with hepatitis B surface antigen (HBsAg) tested in a hospital from 2014 to 2023. Clinical data were captured from the hospital electronic database. Letter of referral after health check was recorded.
Results: A total of 28 940 individuals underwent health check with HBsAg tested. Six hundred and seventy-three HBsAg-positive individuals were eligible for analysis. Overall, 322 (47.8%) individuals received referral to hepatology specialist. There was a trend of increasing referral with time over the 10 years; trend slope (95% confidence interval): 5.0% (3.5%-6.4%) per year; p < 0.001. HBV DNA was tested in 207 (30.8%) individuals. On multivariable analysis, with reference to individuals with no HBV DNA tested, HBV DNA ≥ 2000 IU/mL was the strongest independent factor associated with referral (adjusted odds ratio 21.42; 95% confidence interval 8.79-52.24; p < 0.001). Detectable HBV DNA < 2000 IU/mL had a modest association with referral (adjusted odds ratio 1.84; 95% confidence interval 1.08-3.11; p = 0.024).
Conclusions: Elevated HBV DNA is an important factor associated with specialist referral among HBsAg-positive individuals identified at health check programs. These findings suggest that implementing reflex HBV DNA testing could be a key strategy to improve specialist referral and facilitate linkage to care.
Keywords: hepatitis B virus; hepatitis elimination; linkage to care; screening.
© 2025 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
References
-
- WHO, Global Health Sector Strategy on Viral Hepatitis 2016‐2021. Towards Ending Viral Hepatitis, 2021, https://iris.who.int/handle/10665/246177.
-
- G. L. H. Wong, V. W. K. Hui, T. C. F. Yip, et al., “Universal HBV Vaccination Dramatically Reduces the Prevalence of HBV Infection and Incidence of Hepatocellular Carcinoma,” Alimentary Pharmacology & Therapeutics 56 (2022): 869–877.
-
- The Polaris Observatory Collaborators, “Global Prevalence, Cascade of Care, and Prophylaxis Coverage of Hepatitis B in 2022: A Modelling Study,” Lancet Gastroenterology & Hepatology 8 (2023): 879–907.
-
- C. Q. Pan, L. Zhu, A. S. Yu, Y. Zhao, B. Zhu, and E. Dai, “Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systemic Review and Meta‐Analysis,” Clinical Infectious Diseases 79 (2024): 953–964.
-
- Y. S. Lim, H. L. Y. Chan, S. H. Ahn, et al., “Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate Reduce Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B,” JHEP Reports 5 (2023): 100847.
Grants and funding
LinkOut - more resources
Full Text Sources
